One-Time gene infusion aims to repair hearts in rare genetic condition
Disease control
Recruiting now
This early-stage trial tests a single intravenous dose of AFTX-201, a gene therapy designed to deliver a working copy of the BAG3 gene to heart cells. It enrolls 22 adults aged 18–55 with dilated cardiomyopathy and a BAG3 mutation. The study primarily checks safety and tolerabili…
Phase: PHASE1, PHASE2 • Sponsor: Affinia Therapeutics • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC